Radium 223 Dichloride (Xofigo)®
Common name: Radium 223 Dichloride
Brand name: Xofigo®
What is Radium 223 Dichloride?
Radium 223 Dichloride is a radiopharmaceutical that is used to treat patients with castration-resistant prostate cancer which has spread to the bones, but has not spread to other organs in the body.
How is Radium 223 Dichloride administered?
Radium 223 Dichloride is administered by injection.
What are possible side effects of this treatment?
Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are the most common side effects experienced by those who received radium 223 dichloride. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
- Nausea
- Diarrhea
- Vomiting
- Swelling of the arms or legs
- Low blood cell count
Is Radium 223 Dichloride covered in my province or territory?
Radium 223 Dichloride is covered by provincial drug programs in:
- British Columbia (special authorization)
- Manitoba
- Ontario
- Québec
- Saskatchewan
Radium 223 Dichloride is not covered by provincial drug programs in:
- Alberta
- New Brunswick
- Newfoundland & Labrador
- Nova Scotia
- Prince Edward Island
- Nunavut
- Northwest Territories
- Yukon
Last Reviewed: April 2018